H4 Orphan Pharma is developing two drug candidates. Studies performed on human cell models have demonstrated the efficacy of the molecular mechanism.
554-001: An orally-administered treatment for idiopathic pulmonary fibrosis. To start toxicological and clinical studies, the industrial production of the molecule was launched in 2020. The company is planning to commercialize the treatment under license.
554-002: An eye-drop treatment for dry eye in Sjögren syndrome. Industrial production of the treatment to start toxicological and clinical studies is underway. The company will likely commercialize the treatment under license.